Evidence map›Paper›PMID 24838334›Full record

ArticleAmerican journal of clinical pathology2014

Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens.

Douglas J Hartman, Alyssa M Krasinskas, Shikhar Uttam, Kevin Staton, Rajan Bista, Sumera I Ilyas, Adam Slivka, Randall Brand, Yang Liu

Abstract readEvaluation Study
In one paragraph

Article in American journal of clinical pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Douglas J HartmanFrom the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; hartmandj@upmc.edu.
Alyssa M KrasinskasDepartment of Pathology, Emory University, Atlanta, GA;
Shikhar UttamDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
Kevin StatonDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
Rajan BistaDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
Sumera I IlyasDepartment of Gastroenterology, Mayo Clinic, Rochester, MN.
Adam SlivkaDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
Randall BrandDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
Yang LiuDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA; and.
University of Pittsburgh · USEmory University · USUniversity of Pittsburgh Medical Center · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
MULTIDISCRIPLINARY TRAINING IN DIGESTIVE DISEASEST32DK007198 · NIDDK · MAYO CLINIC ROCHESTER · PI Harmeet Malhi · 1986 to 2026
$8.9M
Novel Nanoscale Single-Cell Analysis of Exfoliative CytologyR01EB016657 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YANG · 2013 to 2016
$1.3M
Partial-wave spectroscopic microscopy for the diagnosis of cholangiocarcinomaR21CA138370 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YANG · 2009 to 2010
$367k
Nano-architecture Based Biomarkers for Cervical Cancer ScreeningR21CA164433 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YANG · 2012 to 2013
$350k
NCATS NIH HHS UL1 TR000005NCI NIH HHS R21 CA138370NCI NIH HHS R21CA138370NCI NIH HHS R21 CA164433NCI NIH HHS R21CA164433NIBIB NIH HHS R01 EB016657NIBIB NIH HHS R01EB016657NIDDK NIH HHS T32 DK007198
6 · The paper itself

Abstract

objectivesThe accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens.

methodsThe SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells.

resultsThe SL-QPM-derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5% from 65.4% of conventional pathology, while maintaining 100% specificity.

conclusionsSL-QPM-derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.

Indexed as

Biomarkers, TumorAdultAgedAged, 80 and overBile Duct NeoplasmsBile DuctsBiopsyCell NucleusEarly Detection of CancerFemaleHumansMaleMiddle AgedNanostructuresSensitivity and SpecificityYoung AdultBiomarkers, TumorGastrointestinalMolecular diagnosticsTechnique

Identifiers

PMID24838334
PMCPMC4131989
OpenAlexW2011732115

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.